Secondary outcomes
The secondary outcomes are described in details in the study protocol (19).
The following secondary outcomes were self-reported:
Psychological well-being, measured by WHO-5 eight weeks postpartum. In the planning of the trial this secondary was the highest prioritised secondary outcome (19). The remaining secondary outcomes were not ranked.Functional ability, measured by General Health Questionnaire (GHQ-12), clinical symptoms of anxiety, measured by the Spielberger State-Trait Anxiety Inventory (STAI), symptoms of depression defined as a cut-off score of ≥11 on the Edinburgh Postnatal Depression Scale (EPDS) were all measured 29–34 weeks of gestation and eight weeks postpartum. Based on a resent Danish study validating the Danish version of the EPDS against a diagnosis of depression in a sample of new mothers, we changed our predefined cut-off scores of ≥10 and ≥13 on the EPDS to a cut-off score of ≥11 (23). Further self-reported secondary outcomes were exclusive breastfeeding at eight weeks postpartum and sick leave in days from intervention start until labour.
The following secondary outcomes were obtained from medical records:
Preeclampsia, gestational age (days) at delivery, preterm delivery (> three weeks before term), induction of labour, mode of delivery (spontaneous delivery, instrumental delivery, or caesarean section), epidural anesthesia during delivery, duration of labour (hours), birth weight (gram), birth length (centimeters), Apgar score (<7 at 5 min), arterial pH (<7.10), antenatal contacts (number), antenatal telephone consultations (number), and length of hospital stay (days).
All secondary outcomes are describes in details in the study protocol (19).